Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.

The oncologist - 6 Sept 2024

Sorah Jonathan D, Deal Allison M, Stein Sophia I, Jonsson Mattias, Innocenti Federico, Turk Anita, Boles Jeremiah C, Irvin William, Basch Ethan M, Sanoff Hanna K, Wood William A

Abstract excerpt

INTRODUCTION: Standard investigator-based adverse events (AE) assessment is via CTCAE for clinical trials. However, including the patient perspective through PRO (patient-reported outcomes) enhances clinicians' understanding of patient toxicity and fosters early detection of AEs. We assessed longitudinal integration of PRO-CTCAE within clinical workflow in a phase II trial. MATERIALS AND METHODS: As a sub-study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Relevance

Share to Colorectal Neoplasms

Share to Feasibility Studies

Share to Irinotecan

Share to Longitudinal Studies

Share to Patient Reported Outcome Measures

Source

Open in PubMed Open full text

Identifiers

PMID: 38828490
DOI: 10.1093/oncolo/oyae121
PMCID: PMC11379639

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.PMID 38828490Read ↗

Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events.Semantic proximity Read ↗

Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.Semantic proximity Read ↗

Reporting of Health-Related Quality of Life Outcome Measures in Genotype based Targeted Therapies for Advanced CancersSemantic proximity Read ↗

Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancerSemantic proximity Read ↗

Patient-Reported Symptom Assessments and Early Chemotherapy Discontinuation in Routine Gastrointestinal Cancer CareSemantic proximity Read ↗

Electronic patient-reported outcome monitoring system for sarcoma patients undergoing drug treatment: A development and feasibility studySemantic proximity Read ↗

Validate Real-World Data-based Endpoint Measures of Cancer Treatment OutcomesSemantic proximity Read ↗

Pilot Trial of an Electronic Patient-Reported Outcome Monitoring System in Patients with Metastatic Breast Cancer Undergoing ChemotherapySemantic proximity Read ↗

ePRO Symptom Follow-Up of Colorectal Cancer Patients Receiving Oxaliplatin-Based Adjuvant Chemotherapy is Feasible and Enhances the Quality of Patient Care: a prospective multicenter studySemantic proximity Read ↗

Implementing electronic patient reported outcome data capture for multi-centre oncology clinical trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.